Premium
Clinical usefulness of oral granisetron hydrochloride for alleviation of delayed nausea and vomiting induced by CPT‐11
Author(s) -
IKEDA M.,
YASUI M.,
FUKUNAGA H.,
SESHIMO I.,
TAKAYAMA O.,
IKENAGA M.,
YAMAMOTO H.,
OHUE M.,
SEKIMOTO M.,
MONDEN M.
Publication year - 2005
Publication title -
european journal of cancer care
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.849
H-Index - 67
eISSN - 1365-2354
pISSN - 0961-5423
DOI - 10.1111/j.1365-2354.2005.00608.x
Subject(s) - granisetron , medicine , vomiting , nausea , palonosetron , regimen , anesthesia , chemotherapy , aprepitant , chemotherapy induced nausea and vomiting , antiemetic
This open label pilot study evaluated the safety and efficacy of the oral 5‐HT3 receptor antagonist granisetron for prophylaxis of delayed chemotherapy‐induced nausea and vomiting (CINV) in 30 patients with advanced or recurrent colorectal cancer. Patients were studied during two cycles of a 5‐week regimen with irinotecan (CPT‐11) and UFT. Patients received prophylactic anti‐emetic therapy that included intravenous granisetron. If Grade 1 or higher severity gastrointestinal symptoms occurred during 6 days after CPT‐11 administration in Cycle 1, then oral granisetron was administered daily for the following 5 days of CPT‐11 in Cycle 2. Sixteen patients (53.3%) experienced delayed CINV in Cycle 1. The incidence of Grade 2 or higher vomiting was 32.1% and 27.7% in Cycles 1 and 2 in males ( P = 0.554) respectively, and 54.6% and 32.4% in females ( P = 0.001) respectively. Granisetron is effective against delayed Grade 2 or higher vomiting induced by CPT‐11/UFT in female patients, although granisetron alone may not sufficiently control nausea induced by this regimen.